• Disc Medicine presented initial Phase 2 RESTORE-PV results for DISC-3405 in polycythemia vera at the 2026 SOHO meeting.
• Data showed improved hematocrit control, fewer phlebotomies, improved symptoms; results reflect iron-restriction effects without relying on phlebotomy.
• DISC-3405 was generally well tolerated; injection-site reactions were infrequent, mild, self-limited.
• Results will be featured in an SOHO oral presentation on Sept. 10.
• Disc expects a broader RESTORE-PV update, including initial Phase 1b sickle cell disease data, by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609091925PRIMZONEFULLFEED9823809) on September 09, 2026, and is solely responsible for the information contained therein.